ArticleAnnals of nuclear medicine2026
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective.AAPS PharmSciTech · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCurrent literature on the fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) features of retroperitoneal ganglioneuroma (GN) remains limited, consisting primarily of isolated case reports. This study therefore aimed to investigate its 18F-FDG PET/CT characteristics to improve recognition among nuclear medicine physicians. MATERIALS AND
methodsIn this retrospective single-center study, 21 patients with pathologically confirmed extra-adrenal retroperitoneal GN who underwent 18F-FDG PET/CT imaging between December 2009 and June 2025 were enrolled. The clinical information, FDG imaging features, and pathological data of the patients were collected and analyzed.
resultsThe study cohort comprised 11 males and 10 females, with a mean age of 37.7 ± 15.4 years. On CT imaging, the lesions typically appeared isodense or hypodense relative to muscle. They were generally large, with a mean size of 9.6 ± 4.8 cm. The morphological presentation was irregular in 14 (66.7%) cases and regular in seven (33.3%) cases. The associated features included calcification (n = 10), fat component (n = 6), and cystic change (n = 1). Of the cases with calcification, four also had a concurrent fat component. None of the cases showed necrosis or hemorrhage. The median maximum standardized uptake value (SUVmax) for the cohort was 2.9 (IQR: 2.2–3.7), with a range from 1.6 to 8.3. Following FDR correction, only calcification showed a significant association with lesion size (p = 0.016, r = 0.800). Other associations with lesion size were also nonsignificant. The corresponding correlation coefficients were r = 0.533 for fat, r = 0.469 for vascular encasement, and r = 0.173 for morphology. Comprehensive analysis, including both univariate and multivariate methods, revealed that no clinicoradiologic and pathologic features served as a robust and independent predictor of SUVmax in this cohort (all p > 0.05).
conclusionOn 18F-FDG PET/CT, GN typically presents as a large, solitary mass with mild-to-moderate FDG avidity. This modality may provide descriptive and supportive information for GN. Calcification is a characteristic feature of GN and is markedly associated with increased lesion size. No clinicoradiologic and pathologic features showed a significant association with SUVmax. These findings require confirmation in future large-scale prospective studies.
Indexed as
Identifiers
41420761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.